Rocket Pharmaceuticals (RCKT) Stock Surges After FDA Approves Groundbreaking Gene Therapy

Key Highlights

• KRESLADI received FDA accelerated approval as a gene therapy treatment for pediatric patients with severe leukocyte adhesion deficiency-I (LAD-I).
• Shares of Rocket Pharmaceuticals rose as high as 9% during premarket hours on Friday, closing approximately 6% higher.
• This marks the first FDA-cleared gene therapy specifically designed to treat severe LAD-I, an ultra-rare and deadly immune disorder affecting children.
• The agency also granted Rocket Pharmaceuticals a Rare Pediatric Disease Priority Review Voucher, which the company intends to sell.
• The greenlight follows a previous rejection in June 2024, after which Rocket provided additional clinical data requested by regulators.

Shares of Rocket Pharmaceuticals rallied Friday after the FDA granted accelerated approval to KRESLADI, a gene therapy for severe LAD-I. RCKT stock surged as much as 9% in premarket activity before moderating to around 6% gains at market open.

Rocket Pharmaceuticals, Inc., RCKT

The accelerated pathway means approval was based on preliminary clinical evidence—particularly improvements in neutrophil CD18 and CD11a surface expression levels. Complete validation of therapeutic effectiveness will require longer-term results from an active trial and a mandated post-approval registry.

KRESLADI, scientifically designated as marnetegragene autotemce, represents an autologous hematopoietic stem cell gene therapy. The treatment is indicated for children diagnosed with severe LAD-I resulting from biallelic mutations in the ITGB2 gene, specifically for those without access to an HLA-matched sibling donor for transplantation.

LAD-I represents an extremely rare inherited immunodeficiency disorder. Patients experience repeated severe infections and face elevated mortality risk during early childhood if left untreated. Within the United States, occurrence rates are estimated between one in 100,000 and one in 200,000 births, with approximately two-thirds presenting as severe cases.

KRESLADI now stands as the inaugural FDA-approved gene therapy addressing this rare condition.

The path to approval encountered obstacles along the way. Regulators rejected Rocket’s initial biologics license application in June 2024, requesting supplementary clinical information before proceeding with review.

Rocket Pharmaceuticals resubmitted its BLA, receiving FDA acceptance in October 2024, with March 28, 2026 established as the target decision date—a timeline the agency honored precisely.

Valuable Pediatric Disease Voucher Enhances Commercial Win

Accompanying the regulatory approval, the FDA awarded Rocket Pharmaceuticals a Rare Pediatric Disease Priority Review Voucher. These transferable vouchers typically fetch hundreds of millions of dollars when sold to larger pharmaceutical companies, representing substantial financial value beyond the approval itself.

Rocket indicated it will explore strategic opportunities to monetize this voucher, strengthening its balance sheet position.

Scientific Development Background

The research foundation supporting KRESLADI’s clinical development received partial funding from the California Institute for Regenerative Medicine. The therapy specifically targets the ITGB2 gene, which produces a critical protein enabling white blood cells to combat infections effectively.

The Cranbury, New Jersey-headquartered biotechnology company has pursued this regulatory milestone for multiple years.

The FDA’s decision deadline for the resubmitted biologics license application was March 28, 2026, and regulators delivered their approval precisely on target.

The post Rocket Pharmaceuticals (RCKT) Stock Surges After FDA Approves Groundbreaking Gene Therapy appeared first on Blockonomi.